TY - JOUR
T1 - Sphingosine-1-phosphate-induced smooth muscle cell migration involves the mammalian target of rapamycin
AU - Tanski, William J.
AU - Nicholl, Suzanne M.
AU - Kim, Dong
AU - Fegley, Allison J.
AU - Roztocil, Elisa
AU - Davies, Mark G.
N1 - Funding Information:
Supported by grants from the American College of Surgeons Junior Faculty Award and from the Mentored Clinical Scientist Development Award, sponsored by the NIH-NHLBI/Lifeline Foundation (K08 HL 67746) (M.G.D.), from the NIH through a National Research Service Award (F32 HL69598-01) (W.J.T.), and from the AHA through a Post Doctoral Fellowship (0225696T) (S.M.N.).
PY - 2005/1
Y1 - 2005/1
N2 - Background: Vascular smooth muscle cell (SMC) migration is an important component of the development of intimal hyperplasia. Sphingosine-1-phosphate (S-1-P) is a lipid released from activated platelets with numerous cellular effects including the stimulation of SMC migration in vitro. We examined the role of the mammalian target of rapamycin and ribosomal p70S6 kinase (p70S6K) in S-1-P-induced SMC migration. Methods: Rat arterial SMCs were cultured in vitro. Linear wound and Boyden microchemotaxis assays of migration were performed in the presence of S-1-P (0.01 to 100 μmol/L) with and without rapamycin (10 nmol/L). Western blotting was performed for phosphorylated and total p70S6K, ERK1/2, and p38MAPK after stimulation with S-1-P (0.1 μmol/L), with and without rapamycin pretreatment. Phosphorylation of p70S6K was also assayed after S-1-P treatment in the presence and absence of inhibitors of PI3 kinase (wortmannin, WN, and LY294002, LY), Akt (AktI), p38MAPK (SB203580), and MEK1 (PD98059). Results: S-1-P stimulated migration of SMCs in both linear wound and Boyden chamber assays compared to control (P <. 05); these responses were inhibited by rapamycin to below the level of control (P <. 05 vs S-1-P alone for both assays) in a dose-dependent manner (inhibitory concentration of 50%, 10 nmol/L). S-1-P stimulated phosphorylation of ERK1/2, p38MAPK, and p70S6K, which peaked at 5 minutes for ERK1/2 and p38MAPK and10 minutes for p70S6K (2-fold increase over control for each, P <. 05). Rapamycin prevented the phosphorylation of p70S6K at the Thr 389 site (which correlates with enzyme activity), reduced ERK1/2 phosphorylation, but had no effect on the Thr 421/Ser 424 site or on p38 MAPK phosphorylation. Wortmannin and LY294002 inhibited phosphorylation of the Thr 389 site of p70S6K. AktI and SB203580 had no effect on p70S6K, whereas PD98059 had a marginal effect. Conclusions: S-1-P-induced SMC migration was completely inhibited by rapamycin, indicating that the p70S6K pathway is involved. This mechanism likely involves modulation of the ERK1/2 pathway. S-1-P stimulates phosphorylation of p70S6K in a MEK1-dependent, PI3 kinase-dependent, but Akt-independent manner.
AB - Background: Vascular smooth muscle cell (SMC) migration is an important component of the development of intimal hyperplasia. Sphingosine-1-phosphate (S-1-P) is a lipid released from activated platelets with numerous cellular effects including the stimulation of SMC migration in vitro. We examined the role of the mammalian target of rapamycin and ribosomal p70S6 kinase (p70S6K) in S-1-P-induced SMC migration. Methods: Rat arterial SMCs were cultured in vitro. Linear wound and Boyden microchemotaxis assays of migration were performed in the presence of S-1-P (0.01 to 100 μmol/L) with and without rapamycin (10 nmol/L). Western blotting was performed for phosphorylated and total p70S6K, ERK1/2, and p38MAPK after stimulation with S-1-P (0.1 μmol/L), with and without rapamycin pretreatment. Phosphorylation of p70S6K was also assayed after S-1-P treatment in the presence and absence of inhibitors of PI3 kinase (wortmannin, WN, and LY294002, LY), Akt (AktI), p38MAPK (SB203580), and MEK1 (PD98059). Results: S-1-P stimulated migration of SMCs in both linear wound and Boyden chamber assays compared to control (P <. 05); these responses were inhibited by rapamycin to below the level of control (P <. 05 vs S-1-P alone for both assays) in a dose-dependent manner (inhibitory concentration of 50%, 10 nmol/L). S-1-P stimulated phosphorylation of ERK1/2, p38MAPK, and p70S6K, which peaked at 5 minutes for ERK1/2 and p38MAPK and10 minutes for p70S6K (2-fold increase over control for each, P <. 05). Rapamycin prevented the phosphorylation of p70S6K at the Thr 389 site (which correlates with enzyme activity), reduced ERK1/2 phosphorylation, but had no effect on the Thr 421/Ser 424 site or on p38 MAPK phosphorylation. Wortmannin and LY294002 inhibited phosphorylation of the Thr 389 site of p70S6K. AktI and SB203580 had no effect on p70S6K, whereas PD98059 had a marginal effect. Conclusions: S-1-P-induced SMC migration was completely inhibited by rapamycin, indicating that the p70S6K pathway is involved. This mechanism likely involves modulation of the ERK1/2 pathway. S-1-P stimulates phosphorylation of p70S6K in a MEK1-dependent, PI3 kinase-dependent, but Akt-independent manner.
UR - http://www.scopus.com/inward/record.url?scp=13244275006&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=13244275006&partnerID=8YFLogxK
U2 - 10.1016/j.jvs.2004.08.058
DO - 10.1016/j.jvs.2004.08.058
M3 - Article
C2 - 15696050
AN - SCOPUS:13244275006
SN - 0741-5214
VL - 41
SP - 91
EP - 98
JO - Journal of Vascular Surgery
JF - Journal of Vascular Surgery
IS - 1
ER -